Navigation Links
Combo Screening Doesn't Spot Early Ovarian Cancer
Date:3/20/2009

Even finding it early may not save lives, researchers say,,,,

FRIDAY, March 20 (HealthDay News) -- A screening regimen that combines ultrasound and a blood test to detect CA125, a marker for ovarian cancer, fails to discover the cancer in its early stages and often results in unnecessary surgery, a new study shows.

This finding contrasts with another recent study that found that these same two tests did find early cancer. Taken together, experts say these studies highlight the need to find an effective screening method for this deadly cancer, which is often called the "silent killer."

"The jury is still out on the efficacy of screening with CA125 and transvaginal ultrasound in terms of reducing the mortality rate of ovarian cancer," said lead researcher Dr. Edward Partridge, director of the University of Alabama Birmingham Comprehensive Cancer Center.

"In this study, we do not have mortality data on the screening versus the non-screening group, so no conclusions can be made of the impact of screening with CA125 and transvaginal ultrasound," he added.

This study only reports data on women who were screened, Partridge noted. "We learned that the positive predictive value for the combination of tests is pretty low -- in the 1 to 1.3 percent range," he said. "A substantial number of the tests are false positives."

In addition, screening with transvaginal ultrasound lead to a higher rate of surgery for positive findings than positive CA125, Partridge said. "Transvaginal ultrasound leads to more 'unnecessary' surgeries," he said.

And a high percentage of the cancers detected through screening were late-stage malignancies, Partridge said. "If you detect them at a late stage, it is unlikely that you are going to impact mortality," he said. "In order to affect mortality, one has to detect them at an earlier stage."

The report is published in the April issue of Obstetrics & Gynecology.

For the study, Partridge's team collected data on 34,261 women who underwent annual screening for CA125 and also had transvaginal ultrasound.

The researchers found that over the four years of screening, transvaginal ultrasound produced more positive findings for cancer than CA125 screening. In fact, CA125 positive tests decreased from 60 percent in the first year to 34 percent in the third year.

Of the 89 invasive ovarian cancers diagnosed, 60 were detected through screening. In addition, 72 percent of the screen-detected cancer were late-stage cancers, the researchers reported.

Partridge noted that even detecting cancer early may not have an impact on mortality. "In any screening trial, the ultimate test of its usefulness is does it impact mortality," he said.

Based on the findings of this study and the study published in the March 10 online edition of The Lancet Oncology, this screening method will not have any effect on mortality, Partridge said. "What we need is a more sensitive and specific screening test," he said.

In that study, a British research team found that screening was able to identify most women with cancer. The combination of the blood test and ultrasound found 90 percent of the cancers, while ultrasound alone found 75 percent of the cancers.

Almost 50 percent of all the cancers found were in an early stage (stage I or II), the researchers noted. And 48 percent of the more invasive ovarian cancers detected were designated as being stage I tumors. Usually, only 28 percent of ovarian cancers are identified in this early stage, the researchers pointed out.

Dr. David G. Mutch, the Ira C. and Judith Gall Professor of Obstetrics and Gynecology at Washington University, St. Louis, and author of an accompanying journal editorial, agreed there is no worthwhile screening test for ovarian cancer as yet.

"Patients who were screened presented at the same stage as they would have if they were unscreened," Mutch said. "There is no good screening test at this point."

Mutch added that there is no reason to screen for ovarian cancer in the general population at this point. "The prevalence of the diseases is so low, one in 2,500, and the specificity of the tests are so low, that we are going to operate on a lot of patients unnecessarily," he said.

More information

For more on ovarian cancer, visit the American Cancer Society.



SOURCES: Edward Partridge, M.D., director, University of Alabama Birmingham Comprehensive Cancer Center; David G. Mutch, M.D., Ira C. and Judith Gall Professor of Obstetrics and Gynecology, Washington University, St. Louis; April 2009, Obstetrics & Gynecology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Radiation and drug combo helps boost efficacy of lung cancer treatment
2. Aerobic, Weight Training Combo Best Against Diabetes
3. New antibiotic drug combo to speed up treatment of tuberculosis
4. Drug Combo Helps Fight Marfan Syndrome
5. Drug Combo Blocks Pain Without Impairing Movement
6. Two-Drug Combo Fights Brain Tumors
7. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
8. Drug Combo Boosts Multiple Myeloma Survival
9. Drug Combos Effective Against Rheumatoid Arthritis
10. Combo PET/CT Scan Helps Spot Breast Cancers Spread
11. Drug Combo With Antibiotic May Slow MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combo Screening Doesn't Spot Early Ovarian Cancer
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
Breaking Medicine Technology: